A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
What is the purpose of this trial?
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.
- Trial withPfizer Inc., U.S. Pharmaceuticals Group
- Ages18 years and older
- Last Updated04/21/2023
- Study HIC#2000033600